Observational analysis showed CAR-iNKT cells have superior cytotoxic activity against leukemia in vivo, suggesting enhanced VLA-4-mediated adhesion may improve immunotherapy outcomes.
Key Points
CAR-iNKT cells significantly reduce leukemia burden in the leptomeningeal space compared to CAR-T cells.
Treatment with CAR-iNKT cells decreased leukemia in bone marrow and meninges at 48 hours post-treatment.
Analysis of adhesion capacity demonstrated higher VLA-4 activity in CAR-iNKT cells over CAR-T cells under shear stress conditions.
These findings highlight the importance of VLA-4 in cellular adhesion and trafficking during leukemia therapy.